Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible enterococcus faecium harboring liasr substitutions

Jose M. Munita, Nagendra N. Mishra, Danya Alvarez, Truc T. Tran, Lorena Diaz, Diana Panesso, Jinnethe Reyes, Barbara E. Murray, Javier A. Adachi, Arnold S. Bayer, Cesar A. Arias

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

High-dose daptomycin (DAP) therapy failed in a neutropenic patient with bloodstream infection caused by a DAP-susceptible Enterococcus faecium (minimum inhibitory concentration, 3 μg/mL) harboring genetic changes associated with DAP resistance, with persistent bacteremia and selection of additional resistances. Daptomycin monotherapy should be used cautiously against DAP-susceptible E. faecium strains with minimum inhibitory concentrations 2 g/mL.

Original languageEnglish (US)
Pages (from-to)1277-1280
Number of pages4
JournalClinical Infectious Diseases
Volume59
Issue number9
DOIs
StatePublished - Nov 1 2014

Keywords

  • Daptomycin
  • Enterococcus faecium
  • resistance
  • treatment failure

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible enterococcus faecium harboring liasr substitutions'. Together they form a unique fingerprint.

Cite this